InMed Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 13, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Shareholders’ Equity
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF SHAREHOLDERS’ EQUITY (unaudited)
| Additional · Accumulated Other | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Note · Common Shares · Paid-in Capital · Accumulated Deficit · Comprehensive Income · Total | |||||||||||||||||
| # · $ · $ · $ · $ · $ | |||||||||||||||||
| Balance June 30, 2023 | 3,328,191 | 77,620,252 | 35,741,115 | (101,400,209) | 128,569 | 12,089,727 | |||||||||||
| Loss for the period | - | - | - | (2,536,828) | - | (2,536,828) | |||||||||||
| Share-based compensation | 8 | - | - | 25,191 | - | - | 25,191 | ||||||||||
| Balance September 30, 2023 | 3,328,191 | 77,620,252 | 35,766,306 | (103,937,037) | 128,569 | 9,578,090 | |||||||||||
| Proceeds from private placement net of issuance costs | 7 | 2,339,779 | 2,316,381 | 2,337,661 | - | - | 4,654,042 | ||||||||||
| Loss for the period | - | - | - | (1,478,185) | - | (1,478,185) | |||||||||||
| Share-based compensation | 8 | - | - | 18,264 | - | - | 18,264 | ||||||||||
| Balance December 31, 2023 | 5,667,970 | 79,936,633 | 38,122,231 | (105,415,222) | 128,569 | 12,772,211 | |||||||||||
| Additional · Accumulated Other | ||||||
|---|---|---|---|---|---|---|
| Note | Common Shares | Paid-in Capital | Accumulated Deficit | Comprehensive Income | Total | |
| # | $ | $ | $ | $ | $ | |
| Balance June 30, 2022 | 650,667 | 70,718,461 | 31,684,098 | (93,452,587) | 128,569 | 9,078,541 |
| Proceeds from private placement net of issuance costs | 90,000 | 333,134 | 4,989,366 | - | - | 5,322,500 |
| Exercise of pre-funded warrants | 168,099 | 1,619,797 | (1,619,378) | - | - | 419 |
| Loss for the period | - | - | - | (3,510,200) | - | (3,510,200) |
| Share-based compensation | - | - | 116,680 | - | - | 116,680 |
| Balance September 30, 2022 | 908,766 | 72,671,392 | 35,170,766 | (96,962,787) | 128,569 | 11,007,940 |
| Proceeds from private placement net of issuance costs | 150,000 | 224,659 | 5,132,848 | - | - | 5,357,507 |
| Exercise of pre-funded warrants | 531,226 | 1,966,373 | (1,966,320) | - | - | 53 |
| Loss for the period | - | - | - | (2,101,087) | - | (2,101,087) |
| Share-based compensation | - | - | 70,638 | - | - | 70,638 |
| Balance December 31, 2022 | 1,589,992 | 74,862,424 | 38,407,932 | (99,063,874) | 128,569 | 14,335,051 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.